DeepMed Research

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough

Phase 2

Completed

Conditions: Common Cold Associated With Cough

Interventions: Drug: N-acetylcysteine
Drug: Placebo

First Posted Date: 2015-03-05

Last Posted Date: 2016-07-11

Lead Sponsor: Novartis

Target Recruit Count: 70

Registration Number: NCT02379637

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Phase 3

Completed

Conditions: Meningitis, Meningococcal, Serogroup B

Interventions: Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine

First Posted Date: 2014-12-02

Last Posted Date: 2016-01-05

Lead Sponsor: Novartis

Target Recruit Count: 55

Registration Number: NCT02305446

Locations: 🇵🇱
01, Novartis Investigational Site, Krakow, Poland

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries

Phase 3

Completed

Conditions: Acute Blunt Soft Tissue Injuries/Contusions

Interventions: Drug: Placebos
Drug: placebo

First Posted Date: 2014-11-14

Last Posted Date: 2017-04-19

Lead Sponsor: Novartis

Target Recruit Count: 215

Registration Number: NCT02290821

Locations: 🇺🇸
US Site, Houston, Texas, United States

A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness

Phase 3

Completed

Conditions: Muscle Soreness

Interventions: Drug: Diclofenac sodium gel 1%
Drug: Placebo

First Posted Date: 2014-10-22

Last Posted Date: 2016-04-05

Lead Sponsor: Novartis

Target Recruit Count: 102

Registration Number: NCT02271854

Locations: 🇺🇸
Lotus Clinical Research, 100 W California Blvd,, Pasadena,, California, United States

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: Afuresertib
Drug: Carfilzomib

First Posted Date: 2014-09-10

Last Posted Date: 2016-05-04

Lead Sponsor: Novartis

Target Recruit Count: 1

Registration Number: NCT02235740

Locations: 🇺🇸
Novartis Investigative Site, Cary, North Carolina, United States

Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age

Phase 3

Completed

Conditions: Rabies Infection

Interventions: Biological: Rabies vaccine
Biological: Rabies vaccines + Rabies immunoglobulins

First Posted Date: 2014-06-27

Last Posted Date: 2017-04-07

Lead Sponsor: Novartis

Target Recruit Count: 885

Registration Number: NCT02177032

Locations: 🇵🇭
1, Research Institute for Tropical Medicine, Muntinlupa, Philippines
🇵🇭
2, Asian Hospital and Medical Center, Muntinlupa, Philippines
🇵🇭
4, De La Salle Health Sciences Institute, Cavite, Philippines

and more 3 locations

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Phase 3

Completed

Conditions: Meningococcal Disease

Interventions: Biological: rMenB+OMV

First Posted Date: 2014-05-19

Last Posted Date: 2017-02-15

Lead Sponsor: Novartis

Target Recruit Count: 239

Registration Number: NCT02141516

Locations: 🇵🇱
31, Novartis Investigational Site, Krakow, Poland
🇵🇱
33, Novartis Investigational Site, Warszawa, Poland
🇵🇱
30, Novartis Investigational Site, Wroclaw, Poland

and more 17 locations

Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days

Withdrawn

Conditions: Invasive Group B Streptococcus Disease

First Posted Date: 2014-03-28

Last Posted Date: 2014-07-24

Lead Sponsor: Novartis

Registration Number: NCT02099149

Locations: 🇿🇦
Respiratory and Meningeal Pathogen Research Unit, Soweto, Gauteng, South Africa

Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine

Phase 3

Completed

Conditions: Acute Migraine

Interventions: Drug: Acetaminophen 250 mg and Aspirin 250 mg
Drug: Placebo

First Posted Date: 2013-10-31

Last Posted Date: 2015-06-11

Lead Sponsor: Novartis

Target Recruit Count: 900

Registration Number: NCT01973205

Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)

Phase 3

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: diclofenac diethylamine, DDEA 2.32% gel
Drug: Placebo

First Posted Date: 2013-10-23

Last Posted Date: 2015-06-03

Lead Sponsor: Novartis

Target Recruit Count: 304

Registration Number: NCT01967550

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy